What place for the new biologics in the treatment of necrotising vasculitides.
Jayne
D
D
D001688:Biological Products / Q000009:adverse effects / Q000191:economics / Q000276:immunology / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D016207:Cytokines / Q000037:antagonists & inhibitors; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007155:Immunologic Factors / Q000627:therapeutic use; D008212:Lymphocyte Depletion / Q000379:methods; D009336:Necrosis / Q000276:immunology / Q000473:pathology; D012074:Remission Induction; D014657:Vasculitis / Q000191:economics / Q000276:immunology / Q000473:pathology / Q000628:therapy*
D001688:Biological Products; D016207:Cytokines; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors